Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinggongshoutao Bolus for aMCI
NCT02982603Phase 4Completed
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qinggongshoutao in amnestic mild cognitive impairment (MCI) (3 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognition Subscale at 52 weeks and Rate of conversion to dementia at 52 weeks. Started May 2015; status: completed.
02
Drugs
qinggongshoutao
03
Conditions
amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT02982603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982603.